Xylem Inc. Reports Q1 2025 Revenue Up 2% to $2.1B

By Tamara Parker • Tuesday, April 29 10:25 • Permanent Link

Xylem Inc. has reported its first-quarter 2025 results, with total revenue reaching $2.1 billion, reflecting a 2% increase on a reported basis and a 3% increase on an organic basis compared to the same period last year. The company's earnings per share stood at $0.69, marking a 10% increase on a reported basis and $1.03 on an adjusted basis, representing a 14% increase.

Net income attributable to Xylem for the quarter was $169 million, or $0.69 per share, with a net income margin increase of 70 basis points to 8.2 percent. Adjusted net income, which excludes certain impacts, was $251 million, or $1.03 per share.

Furthermore, first-quarter adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) margin increased by 120 basis points to 20.4 percent, driven by productivity savings and strong price realization.

Looking ahead, Xylem forecasts full-year 2025 revenue of approximately $8.7 to $8.8 billion, up 1 to 2 percent on a reported basis and 3 to 4 percent on an organic basis. The company expects full-year 2025 adjusted EBITDA margin to be approximately 21.3 to 21.8 percent, an increase of 70 to 120 basis points from its 2024 adjusted results. This outlook results in full-year adjusted earnings per share of $4.50 to $4.70.

Xylem's president and CEO, Matthew Pine, highlighted that the company's first-quarter results exceeded expectations, with organic revenue growth across all segments and a book-to-bill ratio exceeding one. Operating discipline drove 120 basis points of margin expansion and double-digit EPS growth.

The company's operating model transformation, including high-impact culture and process simplification initiatives, is progressing well, strengthening agility and driving improved profitability. Xylem is serving customers more effectively and reducing wasted time and effort internally, enabling faster movement with more focus and accountability.

Following these announcements, the company's shares moved 1.0%, and are now trading at a price of $117.09. For the full picture, make sure to review Xylem's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.